SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

LUNGHI, Barbara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.865
EU - Europa 1.275
AS - Asia 929
Continente sconosciuto - Info sul continente non disponibili 3
AF - Africa 1
OC - Oceania 1
SA - Sud America 1
Totale 7.075
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.843
CN - Cina 429
UA - Ucraina 315
IT - Italia 267
SG - Singapore 253
DE - Germania 211
TR - Turchia 161
GB - Regno Unito 148
SE - Svezia 75
FI - Finlandia 68
PL - Polonia 68
ID - Indonesia 34
BE - Belgio 30
CA - Canada 22
NL - Olanda 22
FR - Francia 19
HK - Hong Kong 16
CZ - Repubblica Ceca 15
VN - Vietnam 12
GR - Grecia 7
IN - India 7
IR - Iran 7
LT - Lituania 6
CH - Svizzera 5
JP - Giappone 4
RO - Romania 4
PT - Portogallo 3
TW - Taiwan 3
AL - Albania 2
ES - Italia 2
EU - Europa 2
IE - Irlanda 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AU - Australia 1
BD - Bangladesh 1
BG - Bulgaria 1
BY - Bielorussia 1
CL - Cile 1
DK - Danimarca 1
JO - Giordania 1
KR - Corea 1
MA - Marocco 1
MK - Macedonia 1
RS - Serbia 1
RU - Federazione Russa 1
Totale 7.075
Salva come PNG Salva come JPEG
Città #
Woodbridge 595
Fairfield 594
Houston 381
Chandler 369
Jacksonville 344
Ashburn 271
Seattle 252
Ann Arbor 239
Wilmington 210
Singapore 204
Cambridge 194
Santa Clara 188
New York 169
Izmir 102
Nanjing 98
Ferrara 97
Boardman 93
Princeton 84
Beijing 74
Warsaw 68
San Diego 57
Milan 44
Dearborn 37
Shanghai 36
Shenyang 36
Jakarta 34
Bremen 31
Brussels 29
Munich 25
Hebei 24
Jiaxing 20
Tianjin 20
Nanchang 19
Redwood City 18
Changsha 16
Hong Kong 16
London 14
Los Angeles 14
Brno 13
Mountain View 13
Auburn Hills 12
Des Moines 12
Kunming 12
Mcallen 12
Norwalk 12
Rome 12
Dong Ket 11
Düsseldorf 10
Redmond 9
Hangzhou 8
Jinan 8
Montréal 8
San Mateo 8
Ottawa 7
Abdullah 6
Chicago 6
Florence 6
Helsinki 6
Bologna 5
Falls Church 5
Monmouth Junction 5
Orange 5
Toronto 5
Verona 5
Zhengzhou 5
Castelcovati 4
Frankfurt am Main 4
Fuzhou 4
Hefei 4
Ningbo 4
Padova 4
Sala 4
Shenzhen 4
Augusta 3
Hyderabad 3
Lusia 3
Mülheim-kärlich 3
Reggio Nell'emilia 3
Tappahannock 3
Washington 3
Addison 2
Albignasego 2
Athens 2
Atlanta 2
Catania 2
Changchun 2
Dronten 2
Falkenstein 2
Ferrara di Monte Baldo 2
Genoa 2
Genova 2
Guangzhou 2
Haikou 2
Hounslow 2
Islington 2
Jinhua 2
Madrid 2
Meppel 2
Milazzo 2
Olomouc 2
Totale 5.435
Salva come PNG Salva come JPEG
Nome #
C6orf10 low-frequency and rare variants in italian multiple sclerosis patients 189
Activated factor VII-antithrombin complex predicts mortality in patients with stable coronary artery disease: a cohort study 165
Combinations of 4 mutations (FV R506Q, FV H1299R, FV Y1702C, PT 20210G/A) affecting the prothrombinase complex in a thrombophilic family 163
An integrated genomic-transcriptomic approach supports a role for the proto-oncogene BCL3 in atherosclerosis 154
Factor XI rs2036914 gene polymorphism and occurrence of adverse events after percutaneous coronary intervention. A prospective evaluation. 148
Polymorphisms at LDLR locus may be associated with coronary artery disease through modulation of coagulation factor VIII activity and independently from lipid profile 145
VITAMIN K-INDUCED MODIFICATION OF COAGULATION PHENOTYPE IN VKORC1 HOMOZYGOUS DEFICIENCY 144
A highly polymorphic microsatellite in the factor V gene is an informative tool for the study of factor V-related disorders 137
Genetic determinants of activated factor VII antithrombin complex plasma concentration include tissue factor, factor VII and endothelial protein C receptor gene variants 137
Changes in expression profiles of internal jugular vein wall and plasma protein levels in multiple sclerosis 135
A heparin cofactor II mutation (HCII Rimini) combined with factor V Leiden or type I protein C deficiency in two unrelated thrombophilic subjects 124
A novel mutation (Leu817Pro) causing type 2A von Willebrand disease. 123
The F11 rs2289252 polymorphism is associated with FXI activity levels and APTT ratio in women with thrombosis 120
Asymptomatic carriership of factor V Leiden and genotypes of the fibrinogen gene cluster 116
FV multiallelic marker detects genetic components of APC resistance contributing to venous thromboembolism in FV Leiden carriers 115
Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia 113
Mutation pattern in clinically asymptomatic coagulation factor VII deficiency 111
A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype 110
An underestimated combination of opposites resulting in enhanced thrombotic tendency 109
New coagulation factor V gene polymorphisms define a single and infrequent haplotype underlying the factor V leiden mutation in Mediterranean populations and Indians 107
Mutations in the R2 FV gene affect the ratio between the two FV isoforms in plasma 107
Molecular bases of CRM+ factor X deficiency: a frequent mutation (Ser334Pro) in the catalytic domain and a substitution (Glul02Lys) in the second EGF‐like domain 106
The factor VIII D1241E polymorphism is associated with decreased factor VIII activity and not with activated protein C resistance levels. 106
A new factor V gene polymorphism (His 1254 Arg) present in subjects of African origin mimics the R2 polymorphism (His 1299 Arg) 103
Venous thromboembolism in young women - Role of thrombophilic mutations and oral contraceptive use 101
Risks factors for highly unstable response to oral anticoagulation: a case-control study 100
A novel factor V null mutation detected in a thrombophilic patient with pseudo-homozygous APC resistance and in an asymptomatic unrelated subject 99
Modulation of factor V levels in plasma by polymorphisms in the C2 domain 99
Does factor V Asp79His (409 G/C) polymorphism influence factor V and APC resistance levels? 98
The factor V Glu1608Lys mutation is recurrent in familial thrombophilia 98
Resistance to activated protein C, associated with oral contraceptives use; effect of formulations, duration of assumption, and doses of oestro- progestins 98
Phenotypic homozygous activated protein C resistance associated with compound heterozygosity for Arg506Gln (factor V Leiden) and His1299 Arg substitutions in factor V 97
Apolipoprotein C-III Strongly Correlates with Activated Factor VII-Anti-Thrombin Complex: An Additional Link between Plasma Lipids and Coagulation 97
Expression profiles of the internal jugular and saphenous veins: Focus on hemostasis genes 97
Increased factor VIII coagulant activity levels in male carriers of the factor V R2 polymorphism 96
Novel phenotype and gamma-glutamyl carboxylase mutations in combined deficiency of vitamin K-dependent coagulation factors 96
null 95
Resistance to activated protein C in healthy women taking oral contraceptives 94
Expression of the normal factor V allele modulates the APC resistance phenotype in heterozygous carriers of the factor V Leiden mutation. 93
Molecular basis of coagulation factor V deficiency caused by the R1698W inter-domain mutation. 93
Performance prediction models based on anthropometric, genetic and psychological traits of Croatian sprinters 93
A missense mutation (Y1702C) in the coagulation factor V gene is a frequent cause of factor V deficiency in the Italian population. 91
Interaction of occupational posture, lifestyle and genetic components of thrombophilia 89
null 88
Detection of new polymorphic markers in the factor V gene: Association with factor V levels in plasma 83
Factor V gene mutations (R2 gene) are associated with coronary artery disease inelderly people 83
Expression Profiles of the Internal Jugular and Saphenous Veins: Focus on Hemostasis Genes 83
Phenotype and genotype expression in pseudohomozygous factor V-LEIDEN - The need for phenotype analysis 80
An Italian Family with a Novel Mutation Causing Type 2A von Willebrand Disease and with Reduced Levels of von Willebrand Factor not Linked with the von Willebrand Factor Gene. 80
Molecular bases of pseudo-homozygous APC resistance: The compound heterozygosity for FV R506Q and a FV null mutation results in the exclusive presence of FV Leiden molecules in plasma 79
Increased Susceptibility to Proteases in Type 2A von Willebrand Disease Associated with two Novel Mutations (Val 867 Glu, Pro 864 His). 78
Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention: Relationship with gene polymorphisms and clinical outcome 77
Factor V markers for the detection of genetic components of APC resistance in venous thrombosis 75
Factor V markers for the detection of genetic components of APC resi stance in venous thrombosis. 71
Severe bleeding and absent ADP-induced platelet aggregation associated with inherited combined CalDAG-GEFI and P2Y12 deficiencies 71
Factor V Levels in a Cohort of Patients Eligible for Oral Anticoagulant Therapy. 70
CMR+ Factor V deficiency Arg2080Cys: A model to investigate altered C2 domain-membrane interaction. 68
Polimorfismi funzionali e terapia anticoagulante 67
Contribution of low density lipoprotein receptor-related protein genotypes to coagulation factor VIII levels in thrombotic women 64
null 63
Functional genetics 63
Functional polymorphisms in the LDLR and pharmacokinetics of Factor VIII concentrates 62
Studio di Mutazioni in Geni dell'Emostasi. 55
The asymptomatic carriership of thrombophilic defects is associated with frequent genotypes of the fibrinogen gene cluster. 55
Expression and characterization of a factor V mutation (E1608K) detected in familial thrombophilia. 54
Evaluation of FV mRNA to define the residual FV expression levels in severe FV deficiency 53
Hemostasis gene expression of the internal jugular and saphenous veins 51
Studio di mutazioni in geni dell’emostasi. 49
Lesioni molecolari ricorrenti sono responsabili di difetti funzionali del fattore VII. 48
Detection of New Polymorphic Markers in the Factor V Gene. 48
Contribution of asialoglycoprotein receptor ASGR2 5’ UTR polymorphisms to full-length FVIII concentrate pharmacokinetics 48
The Asialoglycoprotein Receptor Minor Subunit Gene Contributes to Pharmacokinetics of Factor VIII Concentrates in Hemophilia A 47
Cis-segregation of c.1171c>t stop codon (p.r391*) in serpinc1 gene and c.1691g>a transition (p.r506q) in f5 gene and selected gwas multilocus approach in inherited thrombophilia 45
F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes 44
The asialoglycoprotein receptor ASGR2 5’ UTR polymorphisms influence several parameters of full-length FVIII concentrate pharmacokinetics 42
Aptamer-modified FXa generation assays to investigate hypercoagulability in plasma from patients with ischemic heart disease 36
In vivo modulation of a dominant-negative variant in mouse models of von Willebrand disease type 2A 33
Combination of Genomic and Transcriptomic Approaches Highlights Vascular and Circadian Clock Components in Multiple Sclerosis 32
Combination of CLEC4M rs868875 G-Carriership and ABO O Genotypes May Predict Faster Decay of FVIII Infused in Hemophilia A Patients 28
The p.P1127S pathogenic variant lowers von Willebrand factor levels through higher affinity for the macrophagic scavenger receptor LRP1: Clinical phenotype and pathogenic mechanisms 21
Influence of low-density lipoprotein (LDL) receptor-related protein and ABO blood group genotypes on factor XI levels. 20
Modulation of factor VIII pharmacokinetics by genetic components in factor VIII receptors 17
Whole-Exome Sequencing in a Family with an Unexplained Tendency for Venous Thromboembolism: Multicomponent Prediction of Low-Frequency Variant Deleteriousness and of Individual Protein Interaction 16
Factor V Kuwait alias factor V R3: A rare polymorphism of uncertain functional significance 15
Association of membranous nephropathy with familial resistance to activated protein C 11
In vitro and ex vivo rescue of a nonsense mutation responsible for severe coagulation factor V deficiency 9
Genetic components in factor VIII receptors for individual and genotype-modeled hemophilia A treatment 8
Reduced inhibition of activated prothrombin by heparin and venous thromboembolism: heparin resistance revisited 5
Totale 7.206
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.121
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.121
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020960 0 0 0 0 98 182 152 159 118 154 58 39
2020/20211.119 110 101 76 118 38 100 91 116 41 138 134 56
2021/2022903 96 87 47 71 50 18 54 47 21 59 83 270
2022/2023902 93 78 24 109 130 130 67 76 100 15 46 34
2023/2024563 34 39 18 20 36 183 9 26 17 7 13 161
2024/2025550 44 31 172 66 237 0 0 0 0 0 0 0
Totale 7.206